US_PI.jpg

Zum Herunterladen der Prosigna®-Packungsbeilage wählen Sie bitte unten die gewünschte Sprache aus:

 

nCounter_Dx_manual.jpg

nCounter® Dx-Analysesystem Bedienungsanleitung

Zum Herunterladen des Bedienungsanleitung für das nCounter® Dx Analysesystem wählen Sie bitte unten die gewünschte Sprache aus.

 

Prosigna_data_sheet_EX-US_CEPS_PM0007_r7_Final_Page_1.png

Prosigna®-Produktdatenblatt

Hier klicken um das Prosigna®-Produktdatenblatt herunterzuladen.

 

 get_adobe_reader.png

 

Verzeichnis der Publikationen

Intrinsische Subtypen

Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752. Siehe Artikel
Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869-10874. Siehe Artikel
Sørlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418-8423. Siehe Artikel
Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006;355(6):560-569. Siehe Artikel

PAM 50

Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-1167. Siehe Artikel
Nielsen TO, Parker JS, Leung S, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res. 2010;16(21):5222-5232. Siehe Artikel
Chia SK, Bramwell VH, Tu D, et al. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res. 2012;18(16):4465-4472. Siehe Artikel
Cheang MC, Voduc KD, Tu D, et al. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clin Cancer Res. 2012;18(8):2402-2412. Siehe Artikel
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70. Siehe Artikel

Prosigna®

Dowsett M, Sestak I, Lopez-Knowles E, et al. Comparison of PAM50 risk of recurrence score with Oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol. 2013;31(22):2783-2790. Siehe Artikel
Gnant M, Filipits M, Mlineritsch B, et al; Austrian Breast and Colorectal Cancer Study Group. Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with HR+ early breast cancer (EBC): an ABCSG study. Presented at: San Antonio Breast Cancer Symposium; December 4-8, 2012; San Antonio, TX. Abstract P2-10-02. Siehe Artikel
Gnant M, Filipits M, Dubsky P, et al. Predicting risk for late metastasis: the PAM50 risk of recurrence (ROR) score after 5 years of endocrine therapy in postmenopausal women with HR+ early breast cancer: a study on 1,478 patients from the ABCSG-8 trial. Presented at: European Society for Medical Oncology IMPAKT 2013 Breast Cancer Conference; May 2-4, 2013; Brussels, Belgium. Abstract 53O_PR. Siehe Artikel
Sestak I, Dowsett M, Sgroi D, et al. Comparison of five different scores for the prediction of late recurrence for oestrogen receptor-positive breast cancer. Presented at: European Society for Medical Oncology IMPAKT 2013 Breast Cancer Conference; May 2-4, 2013; Brussels, Belgium. Abstract 540_PR. Siehe Artikel
Sestak I, Dowsett M, Zabaglo L, et al. Factors predicting late recurrence for estrogen receptor–positive breast cancer. J Natl Cancer Inst. 2013;105(19):1504-1511. Siehe Artikel
Nielsen T, Wallden B, Schaper C, et al. Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens [published online ahead of print March 13, 2014]. BMC Cancer. doi:10.1186/1471-2407-14-177. Siehe Artikel
Gnant M, Dowsett M, Filipits M, et al. Identifying clinically relevant prognostic subgroups in node-positive postmenopausal HR+ early breast cancer patients treated with endocrine therapy: a combined analysis of 2,485 patients from ABCSG-8 and ATAC using the PAM50 risk of recurrence (ROR) score and intrinsic subtype. Presented at: 2013 American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2013; Chicago, IL. Abstract 506. Siehe Artikel
Gnant M, Filipits M, Greil R, et al; Austrian Breast and Colorectal Cancer Study Group. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol. 2014;25(2):339-345. Siehe Artikel
Filipits M, Nielsen TO, Rudas M, et al; Austrian Breast and Colorectal Cancer Study Group. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer [published online ahead of print February 11, 2014]. Clin Cancer Res. 2014;20(5):1298-1305. doi:10.1158/1078-0432.CCR-13-1845. Siehe Artikel
Sestak I, Cuzick J, Dowsett M, et al; Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score. J Clin Oncol. 2014 Oct 20. pii: JCO.2014.55.6894. Siehe Artikel
 

 

 

JCO_cover.jpg

Klinische Validierungsstudie TransATAC

Hier klicken für den Zugriff auf den Artikel über die klinische Validierungsstudie TransATAC, verfügbar über das Journal of Clinical Oncology

 

Klinische Validierung

img_annals_of_oncology.jpg

Klinische Validierungsstudie ABCSG-8

Hier klicken für den Zugriff auf den Artikel über die klinische Validierungsstudie ABCSG-8, verfügbar über Annals of Oncology.

Analytische Validierung

img_BMC_cancer_study.png

Analytische Validierungsstudie

Hier klicken für den Zugriff auf den Artikel über die analytische Validierungsstudie, verfügbar über BMC Cancer.

 

NCCN Patient Resources

Click here to access the NCCN Patient Resources page.

Prosigna is indicated for use in postmenopausal women with hormone receptor-positive, node-negative (Stage I or II) or node-positive (Stage II or IIIA) early-stage breast cancer to be treated with adjuvant endocrine therapy.

 

© 2014-2017 NanoString Technologies, Inc. All rights reserved. NanoString, the NanoString Technologies logo, nCounter, Prosigna and the Prosigna logo are trademarks and/or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.